Revolutionizing Cancer Treatment: Curis' Q4 2025 Update Marks a New Era in Lymphoma and Leukemia Therapies

Curis, a biotechnology company dedicated to delivering innovative cancer treatments, has made significant strides in its mission to improve the lives of patients with lymphoma and leukemia. In their recent Q4 2025 business update call, Curis' leadership highlighted promising developments across multiple clinical studies.

The Take Aim Lymphoma study, a single-arm registrational study evaluating emavusertib in combination with ibrutinib after BTKI therapy, has shown steady progress. As Jim Dentzer, President and Chief Executive Officer, mentioned during the call, this study is on track to support accelerated submissions in both the U.S. and Europe. The collaboration with FDA and EMA underscores the importance of this registrational study, which will provide valuable data on emavusertib's efficacy in treating primary CNS lymphoma.

In an effort to further expand its reach, Curis engaged with key opinion leaders who expressed interest in exploring emavusertib's potential in additional NHL subtypes. This includes a particularly promising area: CLL (Chronic Lymphocytic Leukemia). The current standard of care for CLL patients involves BTK inhibitors, which can only achieve partial responses. However, by adding emavusertib to this regimen and applying a dual blockade on the biologic pathways driving CLL, Curis aims to improve upon this standard. This could result in complete remission or undetectable disease and the potential for time-limited treatment.

The proof of concept study in patients currently on BTKI monotherapy has begun activation at clinical sites in the U.S. and Europe. Initial data are expected at the ASH annual meeting in December, providing a crucial step towards testing this hypothesis in CLL. If successful, adding emavusertib to BTKI could fundamentally change the treatment paradigm for CLL patients.

Moreover, Curis has presented encouraging initial data from their ongoing AML triplet study. This study evaluates the triple combination of emavusertib with azacitidine and venetoclax in AML patients who have achieved complete remission on aza-ven but remain MRD positive. The impressive results, which include five out of eight evaluable patients achieving MRD conversion, further validate the exciting potential of combining emavusertib with azacitidine and venetoclax.

With its steady progress in registrational studies and promising initial data from proof-of-concept studies, Curis is poised to revolutionize cancer treatment. As Jim Dentzer noted during the call, this marks a new era in lymphoma and leukemia therapies, one that has the potential to improve patient outcomes significantly.